Crossingbridge Advisors’s Cartesian Growth Corp II RENE Stock Holding History

Crossingbridge Advisors’s Portfolio RENE Stock Details RENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-140,587	Closed	-$1.71M	–	115
2025 Q3	$1.71M	Sell	140,587 -135,000	-49%	-$1.64M	0.87%	25
2025 Q2	$3.31M	Buy	+275,587	New	+$3.28M	2.91%	13
2025 Q1	–	Sell	-212,111	Closed	-$2.47M	–	97
2024 Q4	$2.47M	Sell	212,111 -578,152	-73%	-$6.69M	0.81%	27
2024 Q3	$9.06M	Buy	790,263 +258,390	+49%	+$2.94M	6.9%	4
2024 Q2	$6M	Hold	531,873	–	–	3.55%	5
2024 Q1	$5.91M	Buy	+531,873	New	+$5.88M	4.47%	3

Crossingbridge Advisors's RENE Position: Q4 2025 in Review

Crossingbridge Advisors sold out of Cartesian Growth Corp II (RENE) in Q4 2025, closing a stake of 140,587 shares — an estimated $1.71M sold.

Crossingbridge Advisors first reported a position in RENE in Q1 2024 and held it in 6 quarters. The position peaked at $9.06M in Q3 2024. 0 funds tracked by Wall St. Rank hold RENE as of Q4 2025.

Crossingbridge Advisors reported no remaining Cartesian Growth Corp II position as of Q4 2025 after selling out during the quarter.
Crossingbridge Advisors sold 140,587 Cartesian Growth Corp II shares in Q4 2025, an estimated $1.71M.
Crossingbridge Advisors first reported a position in Cartesian Growth Corp II in Q1 2024 and held it in 6 quarters.
Crossingbridge Advisors's Cartesian Growth Corp II position peaked at $9.06M in Q3 2024.
0 funds tracked by Wall St. Rank held Cartesian Growth Corp II as of Q4 2025.

Based on Crossingbridge Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.